Number of Shares and Voting Rights of ADOCIA as of June 30 th, 2025
Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of June 30 th, 2025.
* 192,300 free shares have been issued during the month in accordance with the plans detailed in section 5.1.5.2 of the 2024 Universal Registration Document, released on April 29, 2025.
(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
a few seconds ago
- CNET
Two Days Left to Score Babbel for Life at a Special Price
If you've traveled internationally this summer, you know how helpful it could have been to know the language of where you went. But learning a language can take more time than most of us have, especially if you're starting from scratch. Whether you're looking to learn French, Italian or Portuguese, a Babbel subscription can definitely help. With programs available right on your phone, you'll be speaking another languge before you know it. Thankfully, StackSocial has a limited-time offer for the language learning platform right now. Act soon and you can get a lifetime subscription to Babbel for only $135 when you apply the coupon code LEARN. That'll save you 58% off the usual asking price, and it's the kind of deal that you definitely don't want to sleep on. Unfortunately, this kind of deal expires on Aug. 7, so you only have two days left to pick one up. Babbel's extensive language software includes French, German, Indonesian, Italian, Portuguese, Russian, Spanish and Swedish. Lessons are short so you won't find yourself overwhelmed with information. Skill levels range from beginner to advanced and the content is self-paced. And it's right at your fingertips, perfect for any busy person. Hey, did you know? CNET Deals texts are free, easy and save you money. Babbel's speech recognition software offers instant feedback so you know what you're doing right and where things can be improved, and personalized review sessions help reinforce what you've already learned. The Babbel app works on phones and computers and while you do need an internet connection to get the most out of it, an offline mode provides access to key features if you download them ahead of time. Why this deal matters A lifetime subscription is always a good way to avoid adding another monthly fee to your growing collection and it removes the pressure of putting a restrictive timeline on your learning. Plus, buying lifetime access directly from Babbel would normally cost $599. Even with the current promotion, this StackSocial deal beats the price by a long shot. Just make sure to order your subscription before this deal ends on Aug. 7 and remember that you have only 30 days after your purchase to redeem the subscription. This isn't the lowest price we've seen, but it's only $5 more. For a lifetime of learning, it's hard to beat this limited-time deal. Note: Although this is advertised as a lifetime subscription, there are no guarantees that purchases will be supported for life. As we've seen in the past, a change of ownership, a service shutting down or some other unforeseen circumstance may result in your lifetime subscription ending sooner than anticipated.
Business Wire
a few seconds ago
- Business Wire
Paramount Deal Terms Force GAMCO to Receive Cash for its Voting Shares
GREENWICH, Conn.--(BUSINESS WIRE)--As of July 31, 2025, GAMCO Asset Management Inc. ('GAMCO'), an affiliate of GAMCO Investors, Inc. (OTCQX: GAMI), along with certain other affiliates, collectively owned approximately 12.0% of the outstanding class A voting stock of Paramount Global (NasdaqGS: PARAA) ('Paramount') on behalf of its clients. Given the terms of Paramount's pending combination with Skydance Media, in which current holders of the class A voting stock have no opportunity to continue to hold such voting stock, GAMCO is effectively being forced to receive cash for those shares. On July 31, 2025, GAMCO filed a 13D with the Securities and Exchange Commission disclosing it made a cash election under the terms of the transaction for all class A shares held. GAMCO Investors, Inc., through its subsidiaries, manages assets of private advisory accounts (GAMCO), mutual funds and closed-end funds (Gabelli Funds, LLC) and is known for its Private Market Value with a Catalyst™ style of investment.
Business Wire
a few seconds ago
- Business Wire
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
BOSTON--(BUSINESS WIRE)-- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer's Disease (AD) research and treatment by offering a new approach that goes beyond symptom management. Following the recent FDA validation of organoid-based studies, the company has demonstrated a relatively rapid reduction of the Alzheimer's pathology in AD human brain organoids treated with its principal therapy; shown a significant reduction of the Tau protein, acknowledged by the Food and Drug Administration (FDA) as an AD biomarker, in other studies; and established new classes of AD therapeutics. Implementing the company's signature ' Reprogram, Restore, and Rescue ' strategy, researchers introduce healthy porosomes – neuronal secretory nanomachines – into diseased neurons to target the root causes of AD. By restoring the neuron's secretory and metabolic systems, Porosome Therapeutics' first-of-its-kind approach addresses the cellular function of AD rather than traditional symptom management. 'Unlike therapies that merely dissolve beta amyloid plaques, our platform directly targets the core biological dysfunctions of Alzheimer's, restoring both neurotransmission and metabolic integrity,' said Guillermo Marmol, CEO, Porosome Therapeutics. 'Given Alzheimer's is a serious and life-threatening disease with no effective treatment options, and based on our ability to deliver quantifiable, biomarker-driven improvements, including Tau reduction and disease reversal in human brain organoids, we are actively exploring the FDA's accelerated approval pathway.' In recent studies, the company's approach to porosome restoration has been shown to significantly reduce Tau protein levels – a key FDA-approved biomarker of Alzheimer's. The FDA's recent approval of the Tau test is a landmark development in the research for AD therapies, catalyzed by the groundbreaking science of Porosome Therapeutics. Furthermore, the company's therapeutic approach has been validated using FDA-recommended human brain organoid models, demonstrating fast clinical results with a significant reversal of Alzheimer's pathology shown within two weeks. Organoid models are three-dimensional cell cultures derived from stem cells that mimic the structure and function of human organs. 'When using human brain organoids, we're able to observe the molecular activity of the porosome at an entirely new scale,' said Bhanu P. Jena, PhD, Founder and Chairman, Porosome Therapeutics, and a distinguished cell biologist known for his discovery of the porosome nanomachine, the secretory portal of the cell. 'The ability to create an immense impact in just two weeks is a promising step forward and marks an important milestone as we advance the future of Alzheimer's research and care.' In a complementary development, the company is leveraging artificial intelligence (AI) to design proprietary decoy peptides that target and neutralize the toxic beta amyloid peptide (1-42), which is known for disrupting protein-protein interactions within the neuronal porosome complex and impairing neurotransmitter release. These specially designed AI-decoys bind more strongly to the beta amyloid (1-42), diverting the peptide from interfering with essential porosome functions. With these advances, Porosome Therapeutics has identified three distinct therapeutic classes for AD: Small Molecules and Peptides – Cross the blood-brain barrier to restore mitochondrial function. Biologics – Reconstitute the porosome complex to reverse neuronal secretory dysfunction. AI-Designed Peptides – Decoy peptides designed by AI to neutralize beta amyloid peptides (1-42) and protect neurotransmission. Porosome Therapeutics has expanded its portfolio of products to reflect these breakthroughs and the company's commitment to advancing novel treatment modalities beyond the current standard of care. About Porosome Therapeutics, Inc. Porosome Therapeutics, Inc. is a biopharmaceutical company based in Boston that leverages the groundbreaking discovery of the porosome — the cell's essential secretory machinery. The company employs innovative technologies to identify and develop proprietary therapeutics aimed at currently undruggable porosome proteins linked to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. Porosome Therapeutics is the first company to employ a technology platform dedicated to creating novel therapies targeting the porosome, recognized as the universal secretory machinery in cells. This platform is built on decades of research and is supported by over 200 published studies, proving effective against various serious diseases involving secretory defects. The platform focuses on highly specific nanobody-mediated therapies, aiming to significantly reduce drug side effects. Porosome Therapeutics' work on Alzheimer's Disease is carried out through a subsidiary, NeuroTher LLC.
